Ocugen obtains worldwide rights to modifier gene therapy platform – Healio
|
Ocugen obtains worldwide rights to modifier gene therapy platform
Healio An exclusive worldwide license to develop and commercialize ophthalmology products based on technology from the Schepens Eye Research Institute of Massachusetts Eye and Ear has been obtained by Ocugen, according to a company press release. The … |
